Sequential_administration_of_recombinant_human_interleukin-2_and_dacarbazine_in_metastatic_melanoma:_a_multicenter_phase_II_study._Twenty-five_assessable_patients_with_metastatic_melanoma_have_been_entered_in_a_multicenter_phase_II_study_of_two_induction_cycles_of_human_recombinant_interleukin-2(IL2),_18_x_10(6)_IU/m2/d_continuous_intravenous_(IV)_infusion_on_days_1_to_5_and_days_12_to_17._Dacarbazine_(DTIC),_850_mg/m2_IV_bolus_was_given_on_day_26._The_cycle_was_repeated_at_5_weeks._Maintenance_therapy_was_scheduled_3_weeks_after_the_completion_of_induction_treatment,_consisting_of_IL2,_18_x_10(6)_IU/m2/d_for_5_days_alternating_with_DTIC,_850_mg/m2_IV_every_3_weeks,_for_a_total_of_18_weeks._Six_patients_responded_(24%);_two_complete_and_four_partial._Stable_disease_was_seen_in_five_patients._None_of_the_six_patients_with_more_than_two_sites_of_metastases_responded._Maximum_response_was_observed_in_the_first_3_months_of_treatment._Progression-free_periods_of_6_months_and_longer_were_seen_in_the_two_complete_responders_(8_and_17+_months),_in_two_of_the_four_partial_responders_(7_and_12+_months),_and_in_three_of_the_five_patients_with_stable_disease_(9+,_15,_and_17+_months)._Toxicity_included_fever,_skin_rash,_fatigue,_anorexia,_and_diarrhea_in_most_patients._Two_patients_had_a_weight_gain_of_more_than_10%._Eight_patients_needed_intensive_care_for_the_observation_and_treatment_of_a_myocardial_injury_(one_patient),_ventricular_tachycardia_(one),_hypotension_and_oliguria_(four),_and_sepsis_(two)._Sequential_treatment_with_IL2_and_DTIC_appears_to_be_effective_but_not_clearly_better_than_could_be_expected_of_IL2_alone.